The estimated Net Worth of David Green is at least $7.27 Million dollars as of 12 May 2022. Mr. Green owns over 63,345 units of Biostage stock worth over $640,210 and over the last 21 years he sold BSTG stock worth over $6,095,760. In addition, he makes $534,506 as Director at Biostage.
David has made over 30 trades of the Biostage stock since 2011, according to the Form 4 filled with the SEC. Most recently he bought 63,345 units of BSTG stock worth $375,002 on 12 May 2022.
The largest trade he's ever made was exercising 912,807 units of Biostage stock on 3 March 2015 worth over $2,491,963. On average, David trades about 37,962 units every 50 days since 2004. As of 12 May 2022 he still owns at least 158,861 units of Biostage stock.
You can see the complete history of Mr. Green stock trades at the bottom of the page.
David M. Green is Director of the Company. He was Chairman of the Board, President, Chief Executive Officer of Harvard Apparatus Regenerative Technology, Inc. Mr. Green was also the President and a member of the Board of Directors of Harvard Bioscience from March 1996 and its CEO from May 2013, until the spinoff of our company from Harvard Bioscience on November 1, 2013. Mr. Green remains a director of Harvard Bioscience but no longer holds an executive position at Harvard Bioscience. Mr. Green’s previous experiences include working as a strategy consultant with Monitor Company, a strategy consulting company, in Cambridge, Massachusetts and Johannesburg, South Africa from June 1991 until September 1995 and a brand manager for household products with Unilever PLC, a packaged consumer goods company, in London from September 1985 to February 1989. Mr. Green currently sits on the Advisory Board of the Harvard Business School Healthcare Initiative. Mr. Green graduated from Oxford University with a B.A. Honors degree in physics and holds a M.B.A. degree with distinction from Harvard Business School.
As the Director of Biostage, the total compensation of David Green at Biostage is $534,506. There are no executives at Biostage getting paid more.
David Green is 51, he's been the Director of Biostage since 2015. There are 4 older and 2 younger executives at Biostage. The oldest executive at Biostage, Inc. is James Shmerling, 63, who is the Director.
David's mailing address filed with the SEC is 84 OCTOBER HILL RD, SUITE 11, HOLLISTON, MA, 01746.
Over the last 9 years, insiders at Biostage have traded over $962,849 worth of Biostage stock and bought 1,593,581 units worth $3,804,230 . The most active insiders traders include David Green, Capital Llc Dst, and Ronald J Packard. On average, Biostage executives and independent directors trade stock every 79 days with the average trade being worth of $217,604. The most recent stock trade was executed by Capital Llc Dst on 6 April 2023, trading 62,500 units of BSTG stock currently worth $375,000.
Biostage, Inc., a biotechnology company, engages in developing bioengineered organ implants based on its Cellframe technology. The company's Cellframe technology comprises a biocompatible scaffold that is seeded with the recipient's own stem cells. It is developing its Cellframe technology to treat life-threatening conditions of the esophagus, bronchus, or trachea. The company was formerly known as Harvard Apparatus Regenerative Technology, Inc. and changed its name to Biostage, Inc. in March 2016. Biostage, Inc. was founded in 2007 and is headquartered in Holliston, Massachusetts.
Biostage executives and other stock owners filed with the SEC include: